NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $17.24 -0.45 (-2.54%) Closing price 04:00 PM EasternExtended Trading$17.42 +0.18 (+1.07%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Viridian Therapeutics Stock (NASDAQ:VRDN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Viridian Therapeutics alerts:Sign Up Key Stats Today's Range$17.16▼$18.2050-Day Range$13.30▼$28.7752-Week Range$13.18▼$34.29Volume2.80 million shsAverage Volume3.58 million shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/APrice Target$36.14Consensus RatingModerate Buy Company Overview Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders. In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases. Both candidates are being evaluated in multiple clinical trials across North America and Europe, underscoring the company’s commitment to building a robust pipeline of precision biologics. Viridian’s research platform leverages advanced antibody engineering to enhance potency, selectivity and pharmacokinetic properties, supporting the development of differentiated therapies with the potential for best-in-class profiles. Founded in 2020 and headquartered in Boston, Massachusetts, Viridian was established by a team of experienced biotechnology entrepreneurs and scientists. The company completed its initial public offering in 2021 to secure funding for clinical development and manufacturing scale-up. Under the leadership of Chief Executive Officer Mara Aspinall and Chief Medical Officer Michael Rosenzweig, Viridian has formed strategic partnerships with contract development and manufacturing organizations to support its late-stage programs. Viridian’s global footprint extends through clinical sites and collaborative networks aimed at delivering novel treatments to patients worldwide.AI Generated. May Contain Errors. Read More Viridian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreVRDN MarketRank™: Viridian Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 190th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialViridian Therapeutics has a consensus price target of $36.14, representing about 109.6% upside from its current price of $17.24.Amount of Analyst CoverageViridian Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Viridian Therapeutics are expected to grow in the coming year, from ($3.71) to ($2.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -5.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -5.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.44% of the float of Viridian Therapeutics has been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Viridian Therapeutics has recently increased by 8.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.00 News SentimentViridian Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Viridian Therapeutics this week, compared to 4 articles on an average week.Search Interest15 people have searched for VRDN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $19,999,990.00 in company stock, which represents 1.1255% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,999,990.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.40% of the stock of Viridian Therapeutics is held by insiders.Percentage Held by InstitutionsViridian Therapeutics has minimal institutional ownership at this time.Read more about Viridian Therapeutics' insider trading history. Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRDN Stock News HeadlinesViridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350MMay 21 at 1:57 PM | finance.yahoo.comViridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel ProjectMay 19 at 1:30 PM | globenewswire.comJune 12: The Biggest Buying Spree in History?Former tech executive and angel investor Jeff Brown - who picked Bitcoin, Tesla, and Nvidia before surges of up to 52,400% - says the SpaceX IPO on June 12 could trigger the biggest buying spree in market history. Brown is urging investors to get positioned before the IPO date arrives, when shares could double or more on the first day of trading.May 22 at 1:00 AM | Brownstone Research (Ad)Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in SeptemberMay 17, 2026 | businesswire.comThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionMay 17, 2026 | fool.comFairmount Funds Management Llc Acquires 1,176,470 Shares of Viridian Therapeutics (NASDAQ:VRDN) StockMay 15, 2026 | americanbankingnews.comViridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special MeetingMay 14, 2026 | globenewswire.comInsider Buying: Viridian Therapeutics (NASDAQ:VRDN) Director Acquires 1,176,470 Shares of StockMay 14, 2026 | insidertrades.comSee More Headlines VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $31.12 at the start of the year. Since then, VRDN shares have decreased by 44.6% and is now trading at $17.24. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) announced its earnings results on Tuesday, May, 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.06) by $0.16. The company's revenue was up 95.8% on a year-over-year basis. When did Viridian Therapeutics IPO? Viridian Therapeutics (VRDN) raised $9 million in an IPO on Thursday, June 12th 2014. The company issued 850,000 shares at $10.00-$12.00 per share. Who are Viridian Therapeutics' major shareholders? Top institutional investors of Viridian Therapeutics include Bank of America Corp DE (1.13%), Rice Hall James & Associates LLC (0.87%), Eversept Partners LP (0.69%) and Candriam S.C.A. (0.69%). Insiders that own company stock include Fairmount Funds Management Llc, Lara Meisner, Stephen F Mahoney, Thomas W Beetham and Jennifer Tousignant. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viridian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings5/05/2026Today5/22/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 VRDN's financial health is in the Red zone, according to TradeSmith. VRDN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:VRDN CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees50Year FoundedN/APrice Target and Rating Average Price Target for Viridian Therapeutics$36.14 High Price Target$61.00 Low Price Target$20.00 Potential Upside/Downside+109.6%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$342.60 million Net Margins-490.31% Pretax Margin-508.46% Return on Equity-80.19% Return on Assets-48.84% Debt Debt-to-Equity Ratio0.10 Current Ratio15.15 Quick Ratio15.15 Sales & Book Value Annual Sales$70.85 million Price / Sales25.08 Cash FlowN/A Price / Cash FlowN/A Book Value$4.89 per share Price / Book3.53Miscellaneous Outstanding Shares103,070,000Free Float100,601,000Market Cap$1.78 billion OptionableOptionable Beta0.82 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:VRDN) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
